Comparing Durvalumab, Olaparib, and Cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior Bevacizumab: the phase II NRG-GY023 trial 2025

SWOG/NCI phase II dual anti-CTLA-4/PD-1 blockade in rare tumors: nonepithelial ovarian cancer 2024

Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC; SWOG S1507, NCT-02642042) 2023

ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b/2 study 2022